debrisoquin has been researched along with thioridazine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Benitez, J; Caputi, AP; Carrillo, JA; Cobaleda, J; Martines, C; Piñas, B; Spina, E | 1 |
| Hammarlund-Udenaes, M; Hedberg, A; Lidén, A; Movin, G; Nordin, C; Ring, H; Sjöqvist, F; von Bahr, C | 1 |
| Baumann, P; Meyer, JW; Meyer, UA; Woggon, B | 1 |
| Benitez, J; Buemi, AL; Caputi, AP; Cobaleda, J; Garcia, MA; Llerena, A; Piña, B; Spina, E | 1 |
| Berecz, R; de la Rubia, A; Dorado, P; Fernández-Salguero, P; LLerena, A | 1 |
| Berecz, R; de la Rubia, A; Dorado, P; LLerena, A | 1 |
| Berecz, R; Dahl, ML; de la Rubia, A; Dorado, P; Fernández-Salguero, P; LLerena, A | 1 |
| Berecz, R; de la Rubia, A; Dorado, P; Llerena, A; Peñas-Lledó, EM | 1 |
| Guo, B; He, MM; Li, C; Liu, H; Shen, H; Wang, L; Wrighton, SA | 1 |
4 trial(s) available for debrisoquin and thioridazine
| Article | Year |
|---|---|
Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.
Topics: Adult; Antidepressive Agents; Debrisoquin; Humans; Hydroxylation; Male; Mesoridazine; Phenothiazines; Phenotype; Thioridazine | 1991 |
QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.
Topics: Adrenergic Agents; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Biotransformation; Cytochrome P-450 CYP2D6; Debrisoquin; Dose-Response Relationship, Drug; Female; Humans; Hydroxylation; Long QT Syndrome; Male; Middle Aged; Phenotype; Thioridazine | 2002 |
Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Female; Genotype; Humans; Male; Middle Aged; Polymerase Chain Reaction; Psychotic Disorders; Smoking; Thioridazine | 2003 |
No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.
Topics: Alleles; Antipsychotic Agents; Cytochrome P-450 CYP1A2; Debrisoquin; Dose-Response Relationship, Drug; Genotype; Humans; Mental Disorders; Mesoridazine; Phenothiazines; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Smoking; Thioridazine | 2007 |
8 other study(ies) available for debrisoquin and thioridazine
| Article | Year |
|---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Debrisoquine oxidation phenotype during neuroleptic monotherapy.
Topics: Adult; Aged; Antipsychotic Agents; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Humans; Male; Middle Aged; Oxidation-Reduction; Phenotype; Polymorphism, Genetic; Thioridazine | 1991 |
Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type.
Topics: Adult; Debrisoquin; Humans; Oxidation-Reduction; Polymorphism, Genetic; Schizophrenia; Thioridazine | 1990 |
Debrisoquine oxidation in schizophrenic patients treated with neuroleptics.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Debrisoquin; Female; Humans; Hydroxylation; Isoquinolines; Male; Methotrimeprazine; Middle Aged; Oxidation-Reduction; Schizophrenia; Thioridazine | 1988 |
Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Genotype; Humans; Hydroxylation; Male; Mental Disorders; Middle Aged; Thioridazine | 2001 |
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Topics: Atomoxetine Hydrochloride; Cocaine; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Dextromethorphan; Enzyme Inhibitors; Ethanolamines; Fluoxetine; Humans; Hydroxylation; Imipramine; Kinetics; Microsomes; Molecular Structure; Nortriptyline; Polymorphism, Single Nucleotide; Propylamines; Quinidine; Recombinant Proteins; Thioridazine; Tramadol | 2007 |